Overdose may result in blockage of intestine or stomach.
Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pravastatin | Cholestyramine can cause a decrease in the absorption of Pravastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lovastatin | Cholestyramine can cause a decrease in the absorption of Lovastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cerivastatin | Cholestyramine can cause a decrease in the absorption of Cerivastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Simvastatin | Cholestyramine can cause a decrease in the absorption of Simvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Atorvastatin | Cholestyramine can cause a decrease in the absorption of Atorvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosuvastatin | Cholestyramine can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mevastatin | Cholestyramine can cause a decrease in the absorption of Mevastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Pitavastatin | Cholestyramine can cause a decrease in the absorption of Pitavastatin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ursodeoxycholic acid | Cholestyramine can cause a decrease in the absorption of Ursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycochenodeoxycholic Acid | Cholestyramine can cause a decrease in the absorption of Glycochenodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholic Acid | Cholestyramine can cause a decrease in the absorption of Cholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glycocholic acid | Cholestyramine can cause a decrease in the absorption of Glycocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deoxycholic acid | Cholestyramine can cause a decrease in the absorption of Deoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurocholic acid | Cholestyramine can cause a decrease in the absorption of Taurocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chenodeoxycholic acid | Cholestyramine can cause a decrease in the absorption of Chenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Taurochenodeoxycholic acid | Cholestyramine can cause a decrease in the absorption of Taurochenodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tauroursodeoxycholic acid | Cholestyramine can cause a decrease in the absorption of Tauroursodeoxycholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bamet-UD2 | Cholestyramine can cause a decrease in the absorption of Bamet-UD2 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dehydrocholic acid | Cholestyramine can cause a decrease in the absorption of Dehydrocholic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hyodeoxycholic Acid | Cholestyramine can cause a decrease in the absorption of Hyodeoxycholic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deferasirox | Cholestyramine can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ezetimibe | Cholestyramine can cause a decrease in the absorption of Ezetimibe resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Leflunomide | Cholestyramine may increase the excretion rate of Leflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Teriflunomide | Cholestyramine may increase the excretion rate of Teriflunomide which could result in a lower serum level and potentially a reduction in efficacy. |
| Lomitapide | Cholestyramine can cause a decrease in the absorption of Lomitapide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methotrexate | Cholestyramine may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy. |
| Niacin | Cholestyramine can cause a decrease in the absorption of Niacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propranolol | Cholestyramine can cause a decrease in the absorption of Propranolol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raloxifene | Cholestyramine can cause a decrease in the absorption of Raloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Vancomycin | The therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine. |
| Acetaminophen | Cholestyramine can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Propacetamol | Cholestyramine can cause a decrease in the absorption of Propacetamol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluvastatin | The serum concentration of Fluvastatin can be decreased when it is combined with Cholestyramine. |
| Primidone | Cholestyramine can cause a decrease in the absorption of Primidone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenobarbital | Cholestyramine can cause a decrease in the absorption of Methylphenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phenobarbital | Cholestyramine can cause a decrease in the absorption of Phenobarbital resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rosiglitazone | The serum concentration of Rosiglitazone can be decreased when it is combined with Cholestyramine. |
| Spironolactone | The risk or severity of hyperkalemia and metabolic acidosis can be increased when Cholestyramine is combined with Spironolactone. |
| Mycophenolate mofetil | Cholestyramine may increase the excretion rate of Mycophenolate mofetil which could result in a lower serum level and potentially a reduction in efficacy. |
| Mycophenolic acid | Cholestyramine may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy. |
| Acetyldigitoxin | Cholestyramine can cause a decrease in the absorption of Acetyldigitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Deslanoside | Cholestyramine can cause a decrease in the absorption of Deslanoside resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ouabain | Cholestyramine can cause a decrease in the absorption of Ouabain resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Digitoxin | Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Oleandrin | Cholestyramine can cause a decrease in the absorption of Oleandrin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cymarin | Cholestyramine can cause a decrease in the absorption of Cymarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Proscillaridin | Cholestyramine can cause a decrease in the absorption of Proscillaridin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lanatoside C | Cholestyramine can cause a decrease in the absorption of Lanatoside C resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gitoformate | Cholestyramine can cause a decrease in the absorption of Gitoformate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Peruvoside | Cholestyramine can cause a decrease in the absorption of Peruvoside resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Desogestrel | Cholestyramine can cause a decrease in the absorption of Desogestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Megestrol acetate | Cholestyramine can cause a decrease in the absorption of Megestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levonorgestrel | Cholestyramine can cause a decrease in the absorption of Levonorgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Medroxyprogesterone acetate | Cholestyramine can cause a decrease in the absorption of Medroxyprogesterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethisterone | Cholestyramine can cause a decrease in the absorption of Norethisterone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estradiol | Cholestyramine can cause a decrease in the absorption of Estradiol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ethynodiol diacetate | Cholestyramine can cause a decrease in the absorption of Ethynodiol diacetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mifepristone | Cholestyramine can cause a decrease in the absorption of Mifepristone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestimate | Cholestyramine can cause a decrease in the absorption of Norgestimate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ethinylestradiol | Cholestyramine can cause a decrease in the absorption of Ethinylestradiol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Drospirenone | Cholestyramine can cause a decrease in the absorption of Drospirenone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cyproterone acetate | Cholestyramine can cause a decrease in the absorption of Cyproterone acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gestodene | Cholestyramine can cause a decrease in the absorption of Gestodene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dienogest | Cholestyramine can cause a decrease in the absorption of Dienogest resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethynodrel | Cholestyramine can cause a decrease in the absorption of Norethynodrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestrel | Cholestyramine can cause a decrease in the absorption of Norgestrel resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gestrinone | Cholestyramine can cause a decrease in the absorption of Gestrinone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lynestrenol | Cholestyramine can cause a decrease in the absorption of Lynestrenol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ormeloxifene | Cholestyramine can cause a decrease in the absorption of Ormeloxifene resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Chlormadinone | Cholestyramine can cause a decrease in the absorption of Chlormadinone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norgestrienone | Cholestyramine can cause a decrease in the absorption of Norgestrienone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quingestanol | Cholestyramine can cause a decrease in the absorption of Quingestanol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Demegestone | Cholestyramine can cause a decrease in the absorption of Demegestone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nomegestrol acetate | Cholestyramine can cause a decrease in the absorption of Nomegestrol acetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Norethindrone enanthate | Cholestyramine can cause a decrease in the absorption of Norethindrone enanthate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Estetrol | Cholestyramine can cause a decrease in the absorption of Estetrol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydroxyprogesterone caproate | The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Cholestyramine. |
| Clofibrate | Cholestyramine can cause a decrease in the absorption of Clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenofibrate | Cholestyramine can cause a decrease in the absorption of Fenofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gemfibrozil | Cholestyramine can cause a decrease in the absorption of Gemfibrozil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bezafibrate | Cholestyramine can cause a decrease in the absorption of Bezafibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Etofibrate | Cholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ciprofibrate | Cholestyramine can cause a decrease in the absorption of Ciprofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Simfibrate | Cholestyramine can cause a decrease in the absorption of Simfibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ronifibrate | Cholestyramine can cause a decrease in the absorption of Ronifibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium clofibrate | Cholestyramine can cause a decrease in the absorption of Aluminium clofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clofibride | Cholestyramine can cause a decrease in the absorption of Clofibride resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenofibric acid | Cholestyramine can cause a decrease in the absorption of Fenofibric acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Icosapent | Cholestyramine can cause a decrease in the absorption of Icosapent resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indomethacin | Cholestyramine can cause a decrease in the absorption of Indomethacin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nabumetone | Cholestyramine can cause a decrease in the absorption of Nabumetone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ketorolac | Cholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tenoxicam | Cholestyramine can cause a decrease in the absorption of Tenoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Celecoxib | Cholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolmetin | Cholestyramine can cause a decrease in the absorption of Tolmetin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rofecoxib | Cholestyramine can cause a decrease in the absorption of Rofecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Piroxicam | Cholestyramine can cause a decrease in the absorption of Piroxicam resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fenoprofen | Cholestyramine can cause a decrease in the absorption of Fenoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Valdecoxib | Cholestyramine can cause a decrease in the absorption of Valdecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Diclofenac | Cholestyramine can cause a decrease in the absorption of Diclofenac resulting in a reduced serum concentration and potentially a decrease in efficacy. |